COSMO Pharmaceuticals N.V. (COPN) Stock Statistics & Valuation Metrics

COSMO Pharmaceuticals N.V. has a market cap or net worth of CHF1.11B. The enterprise value is CHF1.25B.

COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding. The number of shares has decreased by -2.65% in one year.

COSMO Pharmaceuticals N.V.’s return on equity (ROE) is >-0.01 and return on invested capital (ROIC) is -1.78%.

The current PE Ratio of COSMO Pharmaceuticals N.V. is ―. COSMO Pharmaceuticals N.V.’s PEG ratio is 4.78.

In the last 12 months, COSMO Pharmaceuticals N.V. had revenue of 104.85M and earned -3.63M in profits. Earnings per share was -0.23.

In the last 12 months, operating cash flow was -11.80M and capital expenditures -4.18M, giving a free cash flow of -15.99M billion.

COSMO Pharmaceuticals N.V. pays an annual dividend of CHF1.936, resulting in a dividend yield of 1.82%

COSMO Pharmaceuticals N.V. upcoming earnings date is Jul 23, 2026, Before Open (Confirmed).

COSMO Pharmaceuticals N.V. as a current ratio of 7.18, with Debt / Equity ratio of 0.88%

In the past 12 months, COSMO Pharmaceuticals N.V. has paid 2.59M in taxes.

COSMO Pharmaceuticals N.V. EV to EBITDA ratio is 743.79, with an EV/FCF ratio of -110.58.

COSMO Pharmaceuticals N.V. has CHF122.66M in cash and marketable securities with CHF4.26M in debt, giving a net cash position of CHF118.40M billion.

Gross margin is 48.53%, with operating margin of -10.00%, and net profit margin of -3.46%.

The average price target for COSMO Pharmaceuticals N.V. is CHF145.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy